

## Primex Pharmaceuticals Appoints Jostein Davidsen and Angelo Colombo as Board Members



## Swiss pharmaceutical group Primex Pharmaceuticals AG announces new board members.

Jostein Davidsen brings over 30 years of experience from the international pharmaceutical industry, most recently serving as CEO of Acino Pharmaceuticals in Switzerland.

Mr. Davidsen was the founder of Nycomed Russia-CIS which he built up to be one of the leading pharmaceutical companies in the region, until being sold to Takeda Pharmaceuticals in 2011. Davidsen then became Corporate Officer and Head of the Emerging Markets at Takeda in Zurich. He was named the world's second most influential pharma-industry leader in Emerging Markets by pharma news service Scrip.

Angelo Colombo has 25 years of experience from the pharmaceutical sector. Recently, he was Managing Director at Corden Pharma Spa with extensive experience in the manufacture of pharmaceuticals, especially injectables.

Previously, Mr. Colombo was the Nerviano site leader for Pfizer, one of the largest pharmaceutical R&D centers for oncology in Europe. He was also General Manager at Pierrel, a leading dental anaesthetic manufacturer. In these roles, Colombo obtained FDA and EMEA approvals at all sites, built a new injectable department with the highest technology standards and developed new formulations.

Panu Paappanen, Chairman of the Board, commented: "With these appointments the board gains senior pharma executives to strengthen the strategic expertise in growing our global pharmaceutical business."

Kari Sarvanto, CEO and Co-Founder of Primex, added: "I am delighted that we can attract experienced pharmaceutical professionals to our board, at a time when Primex is progressing to a new and exciting stage of strong and sustainable growth."

Source & Image Credit: Primex Pharmaceuticals AG

Published on : Wed, 17 May 2017